Table 1

Summary of patient and treatment characteristics, and treatment outcomes of the included randomized controlled trials. Outcome data are expressed at 5 years, unless indicated differently

Author (year of publication)Years of inclusionNo of patientsMono/multi centerTreatment armsMedian FU (months)Age (years)FIGO stage (n (%))HT deviceHT temp (median °C)Outcome
IIIIIIIVLC/PCDFSOS
Harima (2001)42 1994–199940MonoRT vs RHT3662 vs 650 (0)0 (0)40 (100)0 (0)Capacitive40.6 10 vs 16* 10 vs 16* 48 vs 58*
Van der Zee (2002)35 1990–1996114MultiRT vs RHT4356 vs 580 (0)22 (19)81 (71)11 (10)RadiativeNA 41 vs 61* NA 27 vs 51*
Vasanathan (2005)1998–2002110MultiRT vs RHT1650 vs 450 (0)56 (51)51 (46)3 (3)Capacitive41.669*NA73*
Lutgens (2016)37 2003–200984MultiCRT vs RHT855318 (21)46 (55)18 (21)2 (3)RadiativeNANA1.15†1.04†
Harima (2016)38 2001–2015101MultiCRT vs RCHT5562 vs 601 (1)26 (26)66 (65)8 (8)Capacitive41.171 vs 8061 vs 7165 vs 78
Minnaar (2019)34 2014–2017202MonoCRT vs RCHT649 vs 480 (0)75 (36)2 (1)129 (63)CapacitiveNA20 vs 39‡ 20 vs 39‡ 82 vs 87‡
Wang (2020)39 2009–2013373MonoCRT vs RCHT6050 vs 517 (2)230 (62)127 (34)9 (2)Capacitive40.5NA83 vs 87 72 vs 82
  • Bold type indicates significant difference.

  • *Based on 3 years of follow-up.

  • †Based on 7 years of follow-up.

  • ‡Based on 6 months of follow-up.

  • CRT, chemoradiation; DFS, disease free survival; FIGO, International Federation of Gynecology and Obsetrics 2008; FU, follow-up; HT, hyperthermia; LC, local control; NA, not available; OS, overall survival; PC, pelvic control; RCHT, chemoradiation with hyperthermia; RHT, radiotherapy and hyperthermia; RT, radiotherapy.